405 related articles for article (PubMed ID: 37372349)
21. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
22. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
23. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
24. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
[TBL] [Abstract][Full Text] [Related]
25. Advances in immunotyping of colorectal cancer.
Wu Y; Zhuang J; Qu Z; Yang X; Han S
Front Immunol; 2023; 14():1259461. PubMed ID: 37876934
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of MSI Cancer: Facts and Hopes.
Wilbur HC; Le DT; Agarwal P
Clin Cancer Res; 2024 Apr; 30(8):1438-1447. PubMed ID: 38015720
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
29. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma.
Ma YT; Yang HL; Yan L; Hua F; Wang DG; Xu GY; Li Y; Xue YJ; Qin YJ; Sha D; Ning H; Zhao MQ; Yao ZG
Pathol Oncol Res; 2022; 28():1610638. PubMed ID: 36338826
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review.
Mei WJ; Mi M; Qian J; Xiao N; Yuan Y; Ding PR
Front Immunol; 2022; 13():1019582. PubMed ID: 36618386
[TBL] [Abstract][Full Text] [Related]
32. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
33. The impact of microsatellite stability status in colorectal cancer.
Gupta R; Sinha S; Paul RN
Curr Probl Cancer; 2018 Nov; 42(6):548-559. PubMed ID: 30119911
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
Battaglin F; Naseem M; Lenz HJ; Salem ME
Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
37. The clinical utility of microsatellite instability in colorectal cancer.
Diao Z; Han Y; Chen Y; Zhang R; Li J
Crit Rev Oncol Hematol; 2021 Jan; 157():103171. PubMed ID: 33290824
[TBL] [Abstract][Full Text] [Related]
38. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
40. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
